Activiomics Inks Deal with UCB; Aims to Raise $1M in Venture Funding Early Next Year

The agreement calls for the company to apply its mass spec-based phosphoproteomics platform to the study of cell signaling pathways targeted by UCB's therapeutic antibodies and to identify potential protein biomarkers linked to the drugs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.